Remexian Pharma, 51% owned by High Tide, sold 7.6 tonnes of medical cannabis in the quarter ended April 30 2026, the highest distribution volume in its history. This represents a 21% increase from the prior quarter and a 49% rise year over year, based on preliminary, unaudited data subject to revision.

Germany’s medical cannabis imports reached 201.1 tonnes in 2025, more than double the previous year’s 72.9 tonnes. Remexian now handles over 10% of these national import volumes, with licences allowing procurement from 19 countries including Canada.

High Tide plans to leverage its Canadian procurement network and Remexian’s distribution platform to methodically enter additional European markets, focusing on capital-efficient growth. Management intends to build a repeatable distribution engine that captures share in Germany while pursuing expansion under evolving regulatory conditions.